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Purpose
To investigate efficacy and safety of anakinra in systemic-
onset juvenile idiopathic arthritis patients. To assess treat-
ment effect on gene expression profiling, immune
response to anti-pneumococcal Pneumo23 vaccine,
serum amyloid A level, serum ferritin level and the per-
centage of glycosylated ferritin.
Methods
Multicenter randomized double-blind trial. The primary
objective was to compare the efficacy of a one-month
treatment with anakinra to a placebo between 2 groups of
12 patients each. Response was defined by 30% improve-
ment of pediatric ACR core-set criteria for JIA, resolution
of fever and systemic symptoms and normalization or a
decrease of at least 50% of both CRP and first hour ESR
compared to baseline. Intention-to-treat analysis. Second-
ary objectives included tolerance and efficacy assessment
over 12 months and treatment effect on blood gene
expression profiling.
Results
At one month, there was a significant difference in the
response rate between patients treated with anakinra (8/
12) and placebo (1/12). During the double-blind phase,
the number of adverse events, mainly pain to injections,
was similar between both groups. Ten patients from the
placebo group switched to anakinra at Month 1 and 9
were responders at month 2. Eight patients discontinued
anakinra before Month 12: painful injections during the
double-blind phase (2 patients, both on placebo), ileo-
colic symptoms leading to the diagnosis of Crohn's dis-
ease (1 patient), transient hepatic cytolysis (one case),
lack of efficacy or a disease flare (4 cases). Gene expression
profile analyses showed a set of gene pathways dysregu-
lated in SOJIA whose expression dramatically changed
upon anakinra treatment.
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